Key Points
- Progyny CFO Mark Livingston sold 2,139 shares for $64,170 at an average price of $30 under a pre-arranged Rule 10b5-1 plan. He retained 70,314 shares after the sale.
- Progyny reported quarterly EPS of $0.52, beating the $0.31 consensus estimate, and revenue of $341.25 million, slightly above expectations. Revenue rose 8.9% year over year.
- Analysts cited in the article give Progyny a “Moderate Buy” consensus and an average price target of $34.92; several recently raised their targets, including Leerink Partners to $38.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) CFO Mark Livingston sold 2,139 shares of Progyny stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $30.00, for a total transaction of $64,170.00. Following the sale, the chief financial officer directly owned 70,314 shares in the company, valued at $2,109,420. The trade was a 2.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Progyny Stock Performance
Shares of NASDAQ PGNY traded up $0.47 during midday trading on Friday, hitting $34.84. 1,548,505 shares of the company traded hands, compared to its average volume of 956,940. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $35.50. The firm has a market cap of $2.67 billion, a P/E ratio of 31.96, a P/E/G ratio of 2.03 and a beta of 0.97. The stock has a 50-day moving average price of $27.45 and a 200 day moving average price of $24.59.
Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.31 by $0.21. The business had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. Progyny's quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the business posted $0.15 earnings per share. As a group, equities analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current year.
Key Progyny News
Here are the key news stories impacting Progyny this week:
- Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
- Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
- Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
- Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. William Blair Investment Management LLC boosted its position in shares of Progyny by 10.7% in the third quarter. William Blair Investment Management LLC now owns 645,130 shares of the company's stock worth $16,251,000 after purchasing an additional 62,178 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Progyny by 465.5% in the third quarter. Russell Investments Group Ltd. now owns 128,417 shares of the company's stock worth $3,213,000 after purchasing an additional 105,707 shares during the last quarter. Maryland State Retirement & Pension System grew its holdings in Progyny by 62.0% during the 3rd quarter. Maryland State Retirement & Pension System now owns 17,044 shares of the company's stock valued at $429,000 after buying an additional 6,526 shares in the last quarter. Illinois Municipal Retirement Fund bought a new stake in Progyny in the 3rd quarter worth approximately $888,000. Finally, Leuthold Group LLC bought a new stake in Progyny in the 3rd quarter worth approximately $322,000. 94.93% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. Canaccord Genuity Group set a $35.00 target price on Progyny in a research note on Friday, August 7th. Wall Street Zen lowered shares of Progyny from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 31st. KeyCorp raised their price objective on Progyny from $30.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Zacks Research downgraded shares of Progyny from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 19th. Finally, Leerink Partners increased their price objective on Progyny from $37.00 to $38.00 and gave the company an "outperform" rating in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Progyny presently has an average rating of "Moderate Buy" and an average target price of $34.92.
Check Out Our Latest Report on Progyny
About Progyny
(
Get Free Report)
Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.
Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.
Progyny primarily serves self-insured employers and their employees in the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
